In Escherichia coli a single copy of TnlO confers high-level resistance to tetracycline. Resistance itself results from expression of three distinct mechanisms which normally act together (Shales et al., 1980) . In cells containing two copies of TnlO, the level of resistance to tetracycline was reduced. This was not due to overproduction of the repressor which controls the resistance genes, because strains diploid for an operator-constitutive allele of Tn 10 also exhibited reduced expression of resistance. The negative gene dosage effect resulted from decreased expression of two mechanisms (1 and 2) consequent on enhanced expression of the third mechanism. The net result of increasing the copy number was a decrease in resistance because mechanism 3 was less efficient than mechanisms 1 and 2 in protecting the cell against tetracycline. The DNA sequence responsible for the reduced expression of resistance was contained in the internal BgZII fragment of TnlO. This sequence, which is probably unique to TnlO, may encode the protein which mediates mechanism 3. Elevated levels of this protein probably cause decreased expression of mechanisms 1 and 2.
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In Escherichia coli a single copy of TnlO confers high-level resistance to tetracycline. Resistance itself results from expression of three distinct mechanisms which normally act together (Shales et al., 1980) . In cells containing two copies of TnlO, the level of resistance to tetracycline was reduced. This was not due to overproduction of the repressor which controls the resistance genes, because strains diploid for an operator-constitutive allele of Tn 10 also exhibited reduced expression of resistance. The negative gene dosage effect resulted from decreased expression of two mechanisms (1 and 2) consequent on enhanced expression of the third mechanism. The net result of increasing the copy number was a decrease in resistance because mechanism 3 was less efficient than mechanisms 1 and 2 in protecting the cell against tetracycline. The DNA sequence responsible for the reduced expression of resistance was contained in the internal BgZII fragment of TnlO. This sequence, which is probably unique to TnlO, may encode the protein which mediates mechanism 3. Elevated levels of this protein probably cause decreased expression of mechanisms 1 and 2.
I N T R O D U C T I O N
Gene amplification of plasmid-located antibiotic resistance determinants frequently leads to increased levels of antibiotic resistance. For instance, an increase in gene dosage leads to greater resistance to ampicillin, chloramphenicol and streptomycin (Nordstrom et al., 1972; Uhlin & Nordstrom, 1975 , 1977 . There is a similar relationship for several tetracycline resistance determinants. When the plasmid pSC101, present at 5 copies per chromosome, is linked to ColE1 to produce a hybrid plasmid with a copy number of 16 there is a concomitant increase in tetracycline resistance (Cabello et al., 1976) . The tetracycline resistance determinant on plasmid pRSD 1 is located in a transposon designated Tn 172 1 . Growth of Escherichia coli harbouring pRSDl in the presence of tetracycline leads to an increase in the copy number of the transposon and increased expression of resistance Schmitt et al., 1979) . Cloning'of the tetracycline resistance determinant of RP1 (2 copies per chromosome) into a derivative of RSF2124 (30 copies per chromosome) produces a 3-fold increase in the level of resistance to tetracycline (P. M. Bennett, I. Chopra & S. W. Shales, unpublished data).
In some cases, plasmid-determined tetracycline resistance is encoded by a transposon termed TnlO that is 9300 base pairs long . In contrast to the above findings, Taylor et al. (1977) found that multiple copies of TnlO per cell, obtained by generating a copy number mutant of NR 1 (pRR 12), led to a decrease in resistance of E. coli carrier strains compared with cells harbouring wild-type NR 1. 
I . C H O P R A A N D O T H E R S
Tn 10-mediated tetracycline resistance is subject to negative regulatory control (Yang et al., 1976) , resistance conferred in E . coli by pRR12 (3 pg ml-') relative to NRl (100 pg ml-') might result from a higher level of tetracycline gene repressor owing to a repressor gene dosage effect (see discussion . However, this is an unlikely explanation because expression of resistance coded for by the determinants in pSC 101, pRSD 1 and RP 1, all of which show positive gene dosage effects, is also probably subject to negative regulatory control (Chopra & Howe, 1978; Mattes et al., 1979; Shales et al., 1980; P. M. Bennett, unpublished data) .
Whether a tetracycline resistance determinant shows a positive or a negative gene dosage response may be related to the nature of the structural genes it carries. Thus, the resistance region of Tn 10, which shows a negative response, is genetically distinct from the resistance determinants in pSClOl, pRSDl and RP1 (Mendez et al., 1980) , each of which shows a positive response. The lack of nucleotide sequence homology between the resistance region of Tn 10 and the other determinants clearly implies that the products of Tn 10 differ from those encoded by the other plasmids. Recent studies on expression of Tn 10-mediated resistance (Beck, 1979; Shales et al., 1980) imply that resistance results from the interplay of at least three separate resistance mechanisms each of which may be mediated by separate proteins. To understand fully the negative gene dosage response associated with TnlO it seems necessary to examine expression of each of the three resistance mechanisms as a function of TnlO copy number. Unfortunately the products that mediate the three mechanisms have not yet been unequivocally identified and so cannot be quantified. However, it is possible to determine expression of the resistance mechanisms from phenotypic studies (Shales et al., 1980) . The phenotypes associated with these mechanisms are as follows (Ball et al., 1980; Shales et al., 1980) : (a) A 10-to 20-fold increase in resistance to tetracycline that is not associated with decreased antibiotic accumulation -mechanism 1.
(b) A 4-to 7-fold increase in resistance to tetracycline that is associated with decreased uptake of the antibiotic -mechanism 2. This mechanism results at least partially from accelerated efflux of the drug from resistant bacteria.
(c) A 2-to 3-fold increase in resistance to both tetracycline and its derivative minocycline, that is not associated with decreased accumulation of either antibiotic -mechanism 3.
With wild-type TnlO derived from R100-1, mechanisms 2 and 3 are inducible by tetracycline whereas mechanism 1 is expressed constitutively (Shales et al., 1980) . We have now examined expression of these phenotypes in strains having different numbers of Tn 10 per cell in the hope that we might clarify the basis of the negative gene dosage response exhibited by Tn 10.
M E T H O D S
Bacterial strains and plasmids. The Escherichia coli strains and plasmids used are listed in Table 1 . Some of the plasmids were specifically constructed for this study and their genealogy is described in Figs 1 and 2. Plasmids were constructed according to the methods of Ward & Grinsted (1978), except that buffers were changed after precipitation of DNA by ethanol instead of being removed by dialysis.
General methods. Determination of concentrations of antibiotic causing a 50 % reduction in growth rate (ICs0). estimation of covalently closed circular plasmid DNA content and determination of the accumulation of tetracycline by spectrofluorimetry were performed as described previously (Ball et al., 1980; Shales et al., 1980) .
R E S U L T S

Possible role of repressor in reduced expression of TnlO-mediated tetracycline resistance
The availability of mutants of Tn 10 which express resistance constitutively (Foster, 1977) provides a means to determine whether the tetracycline gene repressor has a role in reducing resistance in the multicopy state. The plasmids pDU300 and pDU301 are reported to contain operator-constitutive (0') mutants of Tn 10 (Foster, 1977) . We confirmed the constitutive phenotypes conferred by these plasmids since exposure of strain UB 15 5 3, which carries pDU30 1, to sub-inhibitory concentrations of tetracycline failed to increase resistance (Table  2) . Furthermore, expression of resistance in a strain (DU1200) in which the constitutive (0') derivative of TnlO had transposed from pDU300 to the chromosome of JC3272 (Foster, 1977) was also constitutive (Table 2 ). In contrast, both strains UB 15 33 and DU309 1, each of which contains wild-type Tn 10, exhibited inducible resistance to tetracycline (Table 2) .
Plasmid pDU301 was transferred to strain DU1203 to produce strain UB6 12 1, which carries constitutive alleles of Tn 10 in both chromosomal and plasmid locations (Table 1) . Its level of resistance to tetracycline was less than that exhibited by cells carrying a determinant in one location only ( Table 2 ). The reduction in resistance cannot be attributed to accumulation of repressor because exposure to a sub-inhibitory level of tetracycline (0-5 pg ml-l) did not enhance resistance (Table 2) .
Further evidence that repressor is not involved in lowering resistance was provided by experiments in which the plasmid R100-1 was introduced into strain DU3091 to produce strain UB5793, which therefore carried wild-type TnlO in both chromosomal and plasmid locations. Its level of resistance to tetracycline following exposure to 0.5 pg tetracycline ml-' was less than that exhibited by DU3091 which carries the determinant in one location only (Table 2 ). Prior exposure of strain UB5793 to higher concentrations of tetracycline (1 -0 and 5 -0 pg rn1-I) failed to increase further its level of resistance to tetracycline (data not shown), which was therefore still lower than that of induced cultures of DU309 1. Again, these results showed that the reduction in resistance cannot be attributed to accumulation of functional repressor molecules.
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Step 2
I
Step 3 Lo 1
Step 4 Step 2 Step I: formation of pUB5502 from R388 as described previously (Ward & Grinsted, 1978) .
Step 2: transposition of TnlO from the chromosome of DU1200 into the small (1 kb) PstI fragment of R388 to form pUB5554 (R388 : :TnlO).
Step 3: ligation of the PstI fragment of pUB5554, containing TnlO, into the single PstI site of pUB5502 to form pUB5555.
Step 4: deletion in vitro, using BglII, of DNA between the BglII sites of TnlO in pUB5555, resulting in the formation of pUB5556 which has lost the 2.7 kb BglII fragment of TnlO. Plasmid pUB5554 has a copy number of 3 per chromosome and pUB5555, 8 per chromosome. Abbreviations for restriction endonucleases: B, BamHI; BII, BglII; E, EcoRI; P, PstI. (kb denotes lo3 base pairs.) Fig. 2 . Construction of plasmids pUB5572, pUB1640 and pUB1641.
Step I: digestion of R388 with BglII to form pUB5572.
Step 2: cloning of the 2.7 kb BglII fragment from pUB5555 ( Fig. 1) into the BglII site of pUB5572 in both orientations to give pUB1640 and pUB1641. Abbreviations for restriction endonucleases: B, BamHI: BII, BglII; E, EcoRI; P, PstI.
Reduced expression of tetracycline resistance in TnlO diploids occurs ajter induction Tetracycline resistance in uninduced cultures of strain UB5793 (containing 2 copies per chromosome of wild-type TnlO) was the sum of the basal levels expressed in the hosts (UB1533 and DU3091) containing only a single copy of TnlO ( Table 2) . We attribute this to a positive gene dosage effect for mechanism 1. Induction of UB1533 and DU3091 led, respectively, to 10-and 5-fold increases in tetracycline resistance ( Table 2) . Similar treatment of UB5793 led only to a 2-fold increase (Table 2) . Therefore, the mechanism which reduced resistance when 2 copies of TnlO were present was inducible by tetracycline. 0 Mean values k 1 standard deviation.
II Strains pre-grown for at least 10 generations in the presence of 0.5 pg tetracycline rn1-Iconstitutive (0') TnlO mutants.
Nature of the product mediating reduced expression in strains carrying more than one copy of TnlO Reduced expression of resistance in the Tn 10 diploid UB5793 occurred after induction thereby implicating a product of the TnlO structural genes in the effect. The response could therefore be mediated either by the product conferring mechanism 2, or that necessary for mechanism 3, because both mechanisms of resistance are inducible in TnlO derived from wild-type RlOO-1 (Shales gt al., 1980) . The plasmid pIP7 was used to investigate the possible role of a mechanism 2 product in the negative gene dosage effect of Tn10. Plasmid pIP7 (with a copy number of 2 per chromosome) mediates resistance to tetracycline but not minocycline (Table 3) , and induction of resistance leads only to decreased accumulation of tetracycline (Shales et al., 1980) . The pIP7-encoded product that confers decreased accumulation is functionally, but probably not structurally, analogous to that determined by TnlO (Ball et al., 1980; Mendez et al., 1980; Shales et al., 1980) . Inducible products of pIP7 did not reduce the expression of Tn 10-mediated resistance to tetracycline or minocycline (Table 3) , thereby implying that the pIP7 product mediating mechanism 2 did not decrease the expression of Tn 10-determined resistance.
Because the reduction in resistance in the TnlO diploids was probably caused by the synthesis of the product required for joint resistance to tetracycline and minocycline (i.e. mechanism 3), we attempted to produce a TnlO derivative in which the structural gene for the joint resistance mechanism was deleted, but which still encoded a functional mechanism 2. concluded that the structural gene for a 36 kilodalton (36K) envelope protein (probably mediating mechanism 2) resides mainly within an internal 2025 base pair (bp) fragment of TnlO produced by cleavage with HpaI (see Fig. 4 ). The TnlO fragment generated by digestion with BglII should therefore contain the structural gene for the 36K protein , but might lack the gene required for expression of mechanism 3. Plasmids PUB 1640 and PUB 164 1 were therefore constructed which contain the internal Bgl I1 fragment of Tn 10 cloned in opposite orientations (Fig. 2) .
Both plasmids conferred decreased accumulation of tetracycline (Table 4 ) consistent with a role for the 36K protein in mechanism 2. However, the recombinant plasmids were not deleted for mechanism 3 because they encoded minocycline resistance (Table 4) . The extent to which mechanism 2 was expressed by these plasmids was inversely related to the level of 6 Mean values f 1 standard deviation.
I1
Strains pre-grown for at least 10 generations in the presence of 0.5 c1& tetracycline ml-I. et al., 1980) . Expression of mechanism 2 was determined from fluorescence data and mechanism 3 from the level of resistance (1C5,) to minocycline. Any residual resistance to tetracycline after accounting for mechanisms 2 and 3 was attributed to expression of mechanism 1 (see text and Table 4 ). Key to strains: (1) UB6012, (2) DU1200, (3) UB6123, (4) UB6014, ( 5 ) DU3091, (6) UB1553, (7) UB6127, (8) DU1203, (9) UB6128, (10) UB6124, (11) UB5793, (12) UB6129, (13) UB6125, (14)UB1529, (15)UB1533, (16) UB6126. resistance to minocycline (Table 4) . Thus, the ratio of minocycline resistance levels for UB6124 :UB6123 was 1.5 and the ratio of tetracycline accumulation for UB6124 :UB6123 was 1-7. The data therefore support the notion that the product involved in resistance to minocycline (mechanism 3) can affect the expression of mechanism 2.
Expression of mechanisms 1 and 2 is inversely related to that of mechanism 3
Data presented in the previous sections imply that elevated levels of the mechanism 3 product conferring joint resistance to tetracycline and minocycline can lead to reduced expression of mechanism 2. However, some simple calculations (see below) predicted that expression of mechanism 1 might also be affected by the mechanism 3 product.
If expression of both mechanisms 1 and 2 is inversely related to that of mechanism 3 we would predict a negative correlation between expression of mechanisms 1 and 2 together and mechanism 3. To test this possible relationship, additional data were collected for strains containing Tn 10 and were combined with results already presented. In each case expression of mechanisms 1, 2 and 3 was determined. Expression of mechanism 3 was obtained directly from the IC,, data for minocycline. Expression of mechanism 2 was calculated using data from fluorimeter traces. For example, expression of mechanism 2 in UB60 12 was estimated as follows: strain UB6012 accumulated 13 -5 units of tetracycline whereas strain JC3272 (the plasmid-free host) accumulated 70 units, and so expression of mechanism 2 in UB6012 was 70/13-5, or 5.2-fold (Table 4) . If mechanism 2 only was expressed it would result in cells with an IC,, of 1.5 pg tetracycline ml-' [i.e. 5.2 x (IC,, of tetracycline for JC3272) = 5.2 x 0.29 pg ml-'I. Expression of mechanism 1 was calculated from the total level of resistance to tetracycline after accounting for expression of mechanisms 2 and 3. For strain UB6012, for example, mechanism 2 contributed a 5-2-fold increase in resistance and mechanism 3 a 3.8-fold increase [i.e. (IC,O of minocycline for UB60 12)/(1C,0 of minocycline for JC3272) =
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1-58/0-421, and so we predict that these mechanisms alone would produce cells with an IC,, of 5.7 pg tetracycline ml-I [i.e. 5.2 x 3.8 x (ICS0 of tetracycline for JC3272) = 5-2 x 3.8 x 0.29 pg ml-'] (Table 4) . Since the actual IC,, of tetracycline for UB6012 was 54.7 pg ml-I (Table 4) , we predict that expression of mechanism 1 in UB6012 contributed a 9.6-fold increase in resistance to tetracycline (i.e. 54.7/5 -7). Calculated values for expression of mechanism 1 in other strains varied between 10-fold and 1-fold (i.e. not expressed). Strains UB6123 and UB6124 are examples of bacteria which did not appear to express mechanism 1 ( Table 4) .
In Fig. 3 , data for a variety of strains containing TnlO are plotted as the theoretical resistance levels conferred by mechanisms 1 and 2 alone versus the logarithm of the minocycline ICS0 (i.e. resistance conferred by mechanism 3). Two parallel lines were obtained which imply a negative correlation between expression of mechanisms 1 and 2 together and mechanism 3. One group of strains (dashed line) was more sensitive to minocycline. The basis of this difference between the two groups is not known.
D I S C U S S I O N
While the work described here was in progress, provided data from which it can also be concluded that the repressor is not involved in reducing the level of resistance in strains containing more than one copy of Tn10. The repressor is also unlikely to be involved because the ratio between its content and the number of operator regions with which it interacts should not change with alterations in TnlO copy number.
As noted in the Introduction, Tn 10-mediated resistance results from the interplay of at least three separate resistance mechanisms, each of which may be mediated by separate Tn 10-encoded proteins. Mechanism 2, involving energy-dependent eMlux of tetracycline, is likely to be mediated by a 36K protein located in the cytoplasmic membrane (Chopra et al., 198l) , whereas mechanism 3 may involve protection of ribosomes by a 15K protein (Levy et al., 1977; Levy & McMurry, 1978) . The nature of the product mediating mechanism 1 is unknown. From the data presented here we conclude that increased expression of resistance to minocycline (mechanism 3) leads to decreased expression of the other mechanisms (mechanisms 1 and 2). Although enhanced expression of mechanism 3 should lead per se to an increase in resistance to tetracycline, the overall level of resistance falls because mechanisms 1 and 2, which are more efficient than mechanism 3, are suppressed.
If the Tn 10 protein which mediates minocycline resistance caused lowered resistance in the multicopy state, then those tetracycline resistance determinants which show a positive gene dosage effect should not encode resistance to minocycline. This is true for pSClO1, RPl (Mendez et al., 1980; Shales et al., 1980) and pRSDl (I. Chopra, unpublished data) . Extrapolation of the continuous line in Fig. 3 to the point where the theoretical expression of mechanism 3 is 1-fold [i.e. log,,(minocycline ICsO) = -0.381 gives an ICs0 value of 29 pg tetracycline ml-' for the combined expression of mechanisms 1 and 2. This corresponds closely to the levels of tetracycline resistance mediated by the determinants in pIP7 and RP1, neither of which confers minocycline resistance (Shales et al., 1980) . Decreased expression of mechanisms 1 and 2 when TnlO is present in several copies might be the consequence of reduced transcription of the respective resistance genes. This model therefore suggests that, in addition to its role in mediating resistance, the mechanism 3 product may bind to DNA and regulate transcription. As yet, there is no evidence to support this contention.
Data presented here, in conjunction with reports by and Beck (1979) , permit conclusions to be drawn on the organization of genes within the resistance region of TnlO (Fig. 4) . The gene for the 36K protein (probably mediating mechanism 2) resides within the HincII fragment of 1275 bp and the structural gene for the repressor lies to the left of this within the HincII fragment of 695 bp (Jorgensen & Horizontal lines designate the general location of RNA polymerase binding sites. The model is compiled from data presented in this paper and by , , Beck (1979) and Shales et al. (1980) . Abbreviations for restriction endonucleases: B, BamHI; BIl, BglII; HII, HincII; HP,, HpaI. . Plasmids PUB 1640 and PUB 164 1 contain both these fragments and additional sequences at either end. The gene conferring joint resistance to tetracycline and minocycline (mechanism 3) and probably coding for the 15K protein (see above) may not be transcribed from a promoter within the BglII fragment because the expression of minocycline resistance conferred by plasmids PUB 1640 and PUB 164 1 is affected by the orientation of the BglII fragment. In plasmids pUB1640 and pUB1641 transcription of the 15K protein may therefore be mediated by R388 promoters that are weaker than the normal TnlO promoter. The structural gene for the 15K protein may therefore reside to the right of the HincII fragment of 1275 bp and its promoter may be located within or to the right of the BgZII cut site on the right of the transposon. concluded that the sequence coding for the carboxy-terminus of the 36K protein probably lies within 100 bp of the HincIIIHpaI site that defines the right hand side of the 2025 bp fragment (Fig. 4) . The gene encoding minocycline resistance may therefore be located in a 540 bp sequence, lying within the 640 bp region defined by the HincIIIHpaI and BgZII cut sites. Assuming that the average molecular mass of an amino acid is 115, than a 15K protein will require a coding sequence of about 400 bp (Chopra & Howe, 1978) , a length consistent with the size of the region thought to contain the structural gene. concluded that the product effecting the multicopy response is coded by a region of TnlO lying to the right of the 640 bp region defined by the HincIIIHpaI and BglII cut sites shown in Fig. 4 . We believe that this region contains the promoter for the 15K protein rather than the structural gene. However, the data of is still consistent with our model because deletions to the right of the 640 bp region in their recombinant plasmids (unrelated to R388) could have eliminated the promoter and abolished synthesis of the 15K protein. Our contention that the region to the right of the 640 bp fragment contains a promoter is also consistent with data showing an RNA polymerase binding site close to the insertion sequence at the right hand side of TnlO (see Fig. 4 ).
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